Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

Phase 1APR-1051Positive

AI Analysis

Summary

Aprea Therapeutics announced an update on its Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051, with accelerated and expanded enrollment and clinical data presentation planned for Q4 2026.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Clinical data presentation planned for Q4 2026; enrollment accelerating and expanding

Importance:5/10

Sentiment:

0.40

WEE1 inhibitororal therapyprecision medicineoncologydose escalationtrial update

Related Companies

$APRE

Read the original article

Published by GlobeNewswire Clinical Studies on July 30, 2026 12:00 PM

Read Original